Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MIRNAS/22Q11DS

Financiado

Cerrado

NEUROGENESIS IN 22Q11.2 DELETION SYNDROME ROLE OF microRNAs

The 22q11.2 deletion syndrome (22qDS) is the most common hemizygous microdeletion syndrome occurring in humans. Individuals with 22qDS show also a variety of neuro−anatomical defects. Our central hypothesis is that altered miRNAs... ver más

31/05/2015

IIT

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-05-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

IIT

0.00€ | Lider

Proyectos interesantes

PID2020-115033RB-I00

Medical Technol...

Data Science

218K€ Cerrado

BFU2016-80273-R

Medical Technol...

Data Science

157K€ Cerrado

PRE2021-098878

Medical Technol...

Genetics

101K€ Cerrado

CNS2023-145402

Medical Technol...

Data Science

200K€ Cerrado

PID2021-128215OB-I00

Medical Technol...

Data Science

230K€ Cerrado

SAF2010-17004

Medical Technol...

Data Science

160K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The 22q11.2 deletion syndrome (22qDS) is the most common hemizygous microdeletion syndrome occurring in humans. Individuals with 22qDS show also a variety of neuro−anatomical defects. Our central hypothesis is that altered miRNAs biogenesis (caused by the hemizygous deletion of Dgcr8, one of the genes located in the 22q11.2 critical region, and required for miRNAs maturation) might impair embryonal/postnatal brain development, thus causing some of the defects observed in brains of 22qDS patients. Our working hypothesis is now further supported by the recent finding that aberrant embryonal neurogenesis is occurring in 22qDS mice and possibly in human patients. However a direct link between altered miRNAs biogenesis and aberrant neurogenesis in 22qDS is still missing. Interestingly, our preliminary results (obtained with hemizygous deletion of Dicer, a gene unrelated to 22qDS, but acting downstream Dgcr8 in the miRNAs maturation pathway) confirm and further expand the observation that reduction in miRNAs dosage affects preferentially the proliferation (or survival) of a basal neural progenitor cells in mice. Thus strengthening the hypothesis of an involvement of miRNAs in the 22qDS. In the current research proposal we aim to investigate whether altered maturation of miRNAs in brains of 22qDS mice, is affecting neurogenesis, and overall, the contribution of altered neurogenesis to the neuro−anatomical/pathological defects observed in 22qDS mice. We then plan to use induced pluripotent stem cells (iPS) from freshly collected fibroblasts of 22qDS patients, and reprogrammed toward neuronal progenitors lineages, in order to verify whether altered miRNAs biogenesis is contributing to some alterations also in a human cellular model of 22qDS. These achievements will allow the straightforward investigation of the cellular defects causing the disease, providing an optimal setting for future systematic drug screenings.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores